Bioniz is leveraging its unique expertise in cytokine biology to develop an entirely new class of peptide-based therapeutics targeting multiple cytokine pathways. Bioniz platform technology allows rationale design of antagonist peptides that selectively inhibit multiple cytokines. The highly specific nature of this approach targets only the pathways that are involved in the disease pathogenesis without compromising the rest of the immune system. This innovative drug development approach enables Bioniz to robustly develop drug candidates for various immune-mediated diseases.
Request more information: * indicates a required field
-
Bringing solutions to global health problems
-
Collaboration is a critical component of scientific discovery.